Showing results (121-130 of 207) with videos related to

Sort By:
Pageof 21
Antimicrobial Agents and Chemotherapy|March 21, 2018
Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrataJustin C Bader, Elizabeth A Lakota, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy|December 14, 2011
Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh modelSharath S Hegde, Olanrewaju O Okusanya, Robert Skinner, et al.
Open Forum Infectious Diseases|July 16, 2020
Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming PatientsPaul G Ambrose, Sujata M Bhavnani, David R Andes, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2016
Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection ModelBrian D VanScoy, Michael Trang, Jennifer McCauley, et al.
Antimicrobial Agents and Chemotherapy|April 10, 2019
Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial PneumoniaJ C Bader, E A Lakota, G E Dale, et al.
Antimicrobial Agents and Chemotherapy|April 28, 2005
Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhiBrent M Booker, Patrick F Smith, Alan Forrest, et al.
Antimicrobial Agents and Chemotherapy|April 15, 2020
Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection ModelBrian D VanScoy, Elizabeth A Lakota, Haley Conde, et al.
Antimicrobial Agents and Chemotherapy|November 14, 2012
Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearanceJürgen B Bulitta, Olanrewaju O Okusanya, Alan Forrest, et al.
AIDS (London, England)|March 15, 1997
Tumour necrosis factor c2 microsatellite allele is associated with the rate of HIV disease progressionS H Khoo, L Pepper, N Snowden, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase InhibitorPaul G Ambrose, Brian D VanScoy, Michael Trang, et al.
Pageof 21